Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 3/20 | 0.37 |
| ▸ | WDR48 | Q8TAF3 | 3/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853891 | 0.90 | NOTUM (0.51) | NOTUMCYP19A1BRS3KEAP1CA2 | |
| SCHEMBL533418 | 0.85 | NOTUM (0.58) | NOTUMCYP19A1BRS3KEAP1USP1 | |
| SCHEMBL16093330 | 0.82 | NOTUM (0.55) | NOTUMCYP19A1BRS3KEAP1TDP1 | |
| SCHEMBL12844428 | 0.82 | CYP19A1 (0.59) | NOTUMCYP19A1BRS3KEAP1USP1 | |
| SCHEMBL6850531 | 0.82 | NOTUM (0.55) | NOTUMCYP19A1BRS3KEAP1USP1 | |
| SCHEMBL10447781 | 0.80 | NOTUM (0.78) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL9756474 | 0.80 | TBXAS1 (0.49) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL6877497 | 0.79 | NOTUM (0.60) | NOTUMCYP19A1BRS3KEAP1USP1 | |
| SCHEMBL4970815 | 0.79 | NOTUM (0.51) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL4966052 | 0.78 | NOTUM (0.50) | NOTUMCYP19A1BRS3KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | NOTUM 4254/4885CYP19A1 1469/4885BRS3 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.